Estrella Immunopharma (NASDAQ:ESLA) Stock Price Up 1.1% – What’s Next?

Estrella Immunopharma, Inc. (NASDAQ:ESLA)’s stock price traded up 1.1% during trading on Thursday . The stock traded as high as $0.77 and last traded at $0.7450. Approximately 29,691 shares traded hands during mid-day trading, a decline of 1% from the average session volume of 30,025 shares. The stock had previously closed at $0.7368.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Estrella Immunopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $8.00.

Estrella Immunopharma Price Performance

The company has a fifty day moving average price of $0.84 and a 200 day moving average price of $1.12. The company has a market cap of $31.99 million, a PE ratio of -3.06 and a beta of 0.88.

Estrella Immunopharma (NASDAQ:ESLA) last announced its earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.04. As a group, sell-side analysts predict that Estrella Immunopharma, Inc. will post -0.29 EPS for the current fiscal year.

Institutional Trading of Estrella Immunopharma

Several institutional investors and hedge funds have recently made changes to their positions in ESLA. Quadrature Capital Ltd purchased a new position in Estrella Immunopharma in the fourth quarter worth $43,000. BlackRock Inc. purchased a new stake in Estrella Immunopharma during the second quarter valued at about $54,000. State Street Corp lifted its stake in Estrella Immunopharma by 93.5% during the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after purchasing an additional 20,900 shares during the last quarter. XTX Topco Ltd lifted its stake in Estrella Immunopharma by 376.9% during the fourth quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after purchasing an additional 39,099 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Estrella Immunopharma in the 4th quarter worth about $88,000. Hedge funds and other institutional investors own 0.35% of the company’s stock.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.